Holen Sie sich die Stockscreener-App
0.95
7.82%
0.0689
Handel nachbörslich:
.93
-0.02
-2.11%
Schlusskurs vom Vortag:
$0.8811
Offen:
$0.921
24-Stunden-Volumen:
34,479
Relative Volume:
0.56
Marktkapitalisierung:
$7.74M
Einnahmen:
$431.40K
Nettoeinkommen (Verlust:
$-1.95M
KGV:
-7.6737
EPS:
-0.1238
Netto-Cashflow:
$-726.80K
1W Leistung:
+10.99%
1M Leistung:
+19.96%
6M Leistung:
-39.49%
1J Leistung:
-12.04%
1-Tages-Spanne:
$0.89
$0.95
1-Wochen-Bereich:
$0.82
$0.95
52-Wochen-Spanne:
$0.65
$4.47
Aptorum Group Ltd Stock (APM) Company Profile
Firmenname
Aptorum Group Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare APM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APM
Aptorum Group Ltd
|
0.95 | 7.18M | 431.40K | -1.95M | -726.80K | -0.1238 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aptorum Group Ltd Aktie (APM) Neueste Nachrichten
XBIO PE Ratio & Valuation, Is XBIO Overvalued - Intellectia AI
APRE PE Ratio & Valuation, Is APRE Overvalued - Intellectia AI
APM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Aptorum Group Soars Over 20% as Market Deciphers Regulatory Chaos and Sector Growth Signals - Bitget
DiamiR merger gives Aptorum (NASDAQ: APM) holders 30% of new Niki BioSolutions - stocktitan.net
Aptorum (NASDAQ: APM) to merge with DiamiR; domestication and share issuance - Stock Titan
Direxion Daily AMZN Bull 2X Shares (NASDAQ:AMZU) Short Interest Up 22.7% in March - Defense World
APTORUM GROUP PB Ratio: 0.29 | Possible Value Trap - GuruFocus
Going concern warning and high risk profile at Aptorum Group (NASDAQ: APM) - Stock Titan
Aptorum (NASDAQ: APM) delays DiamiR merger cutoff to June 30, 2026 - Stock Titan
If You Invested $1,000 in Aptorum Group Ltd (APM) - Stock Titan
Aptorum Group (APM) Stock Analysis Report | Financials & Insights - Benzinga Japan
[6-K] Aptorum Group Ltd Current Report (Foreign Issuer) | APM SEC FilingForm 6-K - Stock Titan
Aptorum, DiamiR publish glioblastoma blood test study By Investing.com - Investing.com South Africa
Aptorum, DiamiR publish glioblastoma blood test study - Investing.com Nigeria
Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania - Bitget
Blood test study takes aim at glioblastoma, deadliest brain cancer - Stock Titan
Aptorum Group Receives Nasdaq Compliance Notification - Intellectia AI
APM | Aptorum Group Limited Class FinancialsIncome Statement - Quiver Quantitative
Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency - The Chronicle-Journal
Biotech Aptorum faces Nasdaq $1 warning but keeps listing for now - Stock Titan
APM Should I Buy - Intellectia AI
Aptorum Group Limited (NASDAQ:APM) Short Interest Up 232.3% in February - Defense World
Aptorum Group Ltd (APM) Income Statement - TradingKey
APMAptorum Group Ltd Latest Stock News & Market Updates - Stock Titan
Can Aptorum Group Limited stock outperform in a bear marketTrade Risk Summary & Target Return Focused Stock Picks - mfd.ru
APM PE Ratio & Valuation, Is APM Overvalued - Intellectia AI
Exit Recap: Is Aptorum Group Limited forming a double bottom2025 Support & Resistance & Weekly Top Stock Performers List - baoquankhu1.vn
CEO Change: Will Aptorum Group Limited stock hit new highs in YEARTrade Performance Summary & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Aptorum Group schedules 2025 annual general meeting for March in Hong Kong By Investing.com - Investing.com South Africa
Aptorum Group schedules 2025 annual general meeting for March in Hong Kong - Investing.com
Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB’s Automated APOE Testing Platform for Alzheimer’s Disease - The Manila Times
Automated Alzheimer’s risk gene test to be vetted in DiamiR lab - Stock Titan
Will Aptorum Group Limited outperform small cap indexes2025 Risk Factors & Precise Buy Zone Identification - mfd.ru
Andean Precious Metals Announces C$83.1 Million Bought Public Secondary Offering of Common Shares - markets.businessinsider.com
Trend Recap: Can Aptorum Group Limited continue delivering strong returnsJuly 2025 Intraday Action & Expert Approved Momentum Ideas - baoquankhu1.vn
Aptorum Group (NASDAQ:APM) vs. BioNxt Solutions (OTCMKTS:BNXTF) Head-To-Head Review - Defense World
Can Aptorum Group Limited stock hit analyst price targetsJuly 2025 Update & Daily Chart Pattern Signal Reports - Улправда
Sentiment Review: Will Aptorum Group Limited stock benefit from upcoming earnings reportsJuly 2025 Pullbacks & Capital Efficiency Focused Ideas - Улправда
Aptorum Group Limited (NASDAQ:APM) Sees Significant Decline in Short Interest - Defense World
Aptorum Group (NASDAQ:APM) Stock Price Up 3.5% – Should You Buy? - Defense World
How interest rate cuts could boost Aptorum Group Limited stockQuarterly Trade Report & Community Verified Watchlist Alerts - Улправда
Can Aptorum Group Limited stock beat market expectations this quarter2025 Support & Resistance & Fast Entry High Yield Stock Tips - Улправда
Aptorum Group Limited (APM) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Aptorum Group Limited stock a buy before product launches - newser.com
The time has not yet come to remove your chips from the table: Aptorum Group Ltd (APM) - Setenews
DiamiR and Aptorum Group (NASDAQ: APM) to Present Alzheimer’s microRNA Data at CTAD 2025 - Stock Titan
Applying Wyckoff theory to Aptorum Group Limited stock2025 Trade Ideas & Fast Gain Swing Alerts - newser.com
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 Conference - Yahoo Finance
Aptorum Group LimitedClass A Ordinary Shares (Nasdaq:APM) Stock Quote - FinancialContent
[F-1] Aptorum Group Ltd Foreign Issuer IPO Registration | APM SEC FilingForm F-1 - Stock Titan
Finanzdaten der Aptorum Group Ltd-Aktie (APM)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):